Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Letter Article

Screening of a Library for Factor VIIa Inhibitors

Author(s): Alexandre Bridoux and Shaker A. Mousa*

Volume 19, Issue 6, 2022

Published on: 21 December, 2021

Page: [481 - 489] Pages: 9

DOI: 10.2174/1570180818666211207125903

Price: $65

Abstract

Background: As an alternative to the anticoagulant’s strategy using direct or indirect anti-Xa drugs, considering other targets upstream in the coagulation cascade such as anti-Factor VIIa could represent an effective and safer strategy in coagulation and pathological angiogenesis.

Objective: The objective of the study was to assess a high technology methodology composed of virtual screening, anticoagulant, and anti-angiogenesis assays to identify potent small-molecule FVIIa inhibitors.

Methods: Chemical databanks were screened to select molecules bearing functional groups that could fit into the active site of FVIIa, which were then tested. Ligands assigned with the lowest scores were retained and then biologically assessed.

Results: From the 500 molecules considered, 8 chemical structures revealed to be effective compounds in vitro and to inhibit angiogenesis in the chick chorioallantoic membrane (CAM) model.

Conclusion: New potent small-molecule FVIIa inhibitors have been identified; further biochemical and chemical developments would be investigated directly from the selected scaffolds.

Keywords: Virtual screening, drug design, FVIIa inhibitors, coagulation, angiogenesis, TF.

Graphical Abstract
[1]
O’Connell, K.M.; Littleton-Kearney, M.T.; Bridges, E.; Bibb, S.C. Evaluating the Joint Theater Trauma Registry as a data source to benchmark casualty care. Mil. Med., 2012, 177(5), 546-552.
[http://dx.doi.org/10.7205/MILMED-D-11-00422] [PMID: 22645881]
[2]
Vincent, J-L.; Rossaint, R.; Riou, B.; Ozier, Y.; Zideman, D.; Spahn, D.R. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding--a European perspective. Crit. Care, 2006, 10(4), R120.
[http://dx.doi.org/10.1186/cc5026] [PMID: 16919168]
[3]
Hodgetts, T.J.; Kirkman, E.; Mahoney, P.F.; Russell, R.; Thomas, R.; Midwinter, M. UK defence medical services guidance for the use of recombinant factor VIIa (rFVIIa) in the deployed military setting. J. R. Army Med. Corps, 2007, 153(4), 307-309.
[http://dx.doi.org/10.1136/jramc-153-04-18] [PMID: 18619169]
[4]
Samama, M.M. Abreges Hemorragies et thrombosis; Elsevier Masson: Issy Les Moulineaux, 2008, vol. 1, pp. 3-13.
[5]
Kakkar, A.K.; Lemoine, N.R.; Scully, M.F.; Tebbutt, S.; Williamson, R.C. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br. J. Surg., 1995, 82(8), 1101-1104.
[http://dx.doi.org/10.1002/bjs.1800820831] [PMID: 7648165]
[6]
Belting, M.; Dorrell, M.I.; Sandgren, S.; Aguilar, E.; Ahamed, J.; Dorfleutner, A.; Carmeliet, P.; Mueller, B.M.; Friedlander, M.; Ruf, W. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat. Med., 2004, 10(5), 502-509.
[http://dx.doi.org/10.1038/nm1037] [PMID: 15098027]
[7]
Mousa, S.A.; Mousa, A.S. Angiogenesis inhibitors: current & future directions. Curr. Pharm. Des., 2004, 10(1), 1-9.
[http://dx.doi.org/10.2174/1381612043453531] [PMID: 14754401]
[8]
(a)Broze, G.J. Thrombosis and Hemorrhage; William and Wilkins: Baltimore, 1998, pp. 77-104.
(b)Carmeliet, P.; Mackman, N.; Moons, L.; Luther, T.; Gressens, P.; Van Vlaenderen, I.; Demunck, H.; Kasper, M.; Breier, G.; Evrard, P.; Müller, M.; Risau, W.; Edgington, T.; Collen, D. Role of tissue factor in embryonic blood vessel development. Nature, 1996, 383(6595), 73-75.
[http://dx.doi.org/10.1038/383073a0] [PMID: 8779717]
[9]
Chen, J.; Bierhaus, A.; Schiekofer, S.; Andrassy, M.; Chen, B.; Stern, D.M.; Nawroth, P.P. Tissue factor--a receptor involved in the control of cellular properties, including angiogenesis. Thromb. Haemost., 2001, 86(1), 334-345.
[http://dx.doi.org/10.1055/s-0037-1616231] [PMID: 11487022]
[10]
Bugge, T.H.; Xiao, Q.; Kombrinck, K.W.; Flick, M.J.; Holmbäck, K.; Danton, M.J.; Colbert, M.C.; Witte, D.P.; Fujikawa, K.; Davie, E.W.; Degen, J.L. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc. Natl. Acad. Sci. USA, 1996, 93(13), 6258-6263.
[http://dx.doi.org/10.1073/pnas.93.13.6258] [PMID: 8692802]
[11]
Toomey, J.R.; Kratzer, K.E.; Lasky, N.M.; Stanton, J.J.; Broze, G.J., Jr. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood, 1996, 88(5), 1583-1587.
[http://dx.doi.org/10.1182/blood.V88.5.1583.1583] [PMID: 8781413]
[12]
Carmeliet, P.; Ferreira, V.; Breier, G.; Pollefeyt, S.; Kieckens, L.; Gertsenstein, M.; Fahrig, M.; Vandenhoeck, A.; Harpal, K.; Eberhardt, C.; Declercq, C.; Pawling, J.; Moons, L.; Collen, D.; Risau, W.; Nagy, A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature, 1996, 380(6573), 435-439.
[http://dx.doi.org/10.1038/380435a0] [PMID: 8602241]
[13]
Ferrara, N.; Carver-Moore, K.; Chen, H.; Dowd, M.; Lu, L.; O’Shea, K.S.; Powell-Braxton, L.; Hillan, K.J.; Moore, M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature, 1996, 380(6573), 439-442.
[http://dx.doi.org/10.1038/380439a0] [PMID: 8602242]
[14]
Nakagawa, K.; Zhang, Y.; Tsuji, H.; Yoshizumi, M.; Kasahara, T.; Nishimura, H.; Nawroth, P.P.; Nakagawa, M. The angiogenic effect of tissue factor on tumors and wounds. Semin. Thromb. Hemost., 1998, 24(3), 207-210.
[http://dx.doi.org/10.1055/s-2007-995843] [PMID: 9701449]
[15]
James, N.J.; Ettelaie, C.; Bruckdorfer, K.R. Inhibition of tissue factor activity reduces the density of cellular network formation in an in vitro model of angiogenesis. Biochem. Soc. Trans., 2002, 30(2), 217-221.
[http://dx.doi.org/10.1042/bst0300217] [PMID: 12023854]
[16]
Tsopanoglou, N.E.; Pipili-Synetos, E.; Maragoudakis, M.E. Thrombin promotes angiogenesis by a mechanism independent of fibrin formation. Am. J. Physiol., 1993, 264(5 Pt 1), C1302-C1307.
[http://dx.doi.org/10.1152/ajpcell.1993.264.5.C1302] [PMID: 7684562]
[17]
Folkman, J.; Cotran, R. Relation of vascular proliferation to tumor growth. Int. Rev. Exp. Pathol., 1976, 16, 207-248.
[PMID: 783062]
[18]
Leek, R.D.; Harris, A.L.; Lewis, C.E. Cytokine networks in solid human tumors: regulation of angiogenesis. J. Leukoc. Biol., 1994, 56(4), 423-435.
[http://dx.doi.org/10.1002/jlb.56.4.423] [PMID: 7523556]
[19]
Strieter, R.M.; Kunkel, S.L.; Elner, V.M.; Martonyi, C.L.; Koch, A.E.; Polverini, P.J.; Elner, S.G. Interleukin-8. A corneal factor that induces neovascularization. Am. J. Pathol., 1992, 141(6), 1279-1284.
[PMID: 1281615]
[20]
Koch, A.E.; Polverini, P.J.; Kunkel, S.L.; Harlow, L.A.; DiPietro, L.A.; Elner, V.M.; Elner, S.G.; Strieter, R.M. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science, 1992, 258(5089), 1798-1801.
[http://dx.doi.org/10.1126/science.1281554] [PMID: 1281554]
[21]
De Larco, J.E.; Wuertz, B.R.; Rosner, K.A.; Erickson, S.A.; Gamache, D.E.; Manivel, J.C.; Furcht, L.T. A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am. J. Pathol., 2001, 158(2), 639-646.
[http://dx.doi.org/10.1016/S0002-9440(10)64005-9] [PMID: 11159200]
[22]
Singh, R.K.; Gutman, M.; Radinsky, R.; Bucana, C.D.; Fidler, I.J. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res., 1994, 54(12), 3242-3247.
[PMID: 8205546]
[23]
Bar-Eli, M. Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology, 1999, 67(1), 12-18.
[http://dx.doi.org/10.1159/000028045] [PMID: 9873223]
[24]
Inoue, K.; Slaton, J.W.; Kim, S.J.; Perrotte, P.; Eve, B.Y.; Bar-Eli, M.; Radinsky, R.; Dinney, C.P. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res., 2000, 60(8), 2290-2299.
[PMID: 10786697]
[25]
Arenberg, D.A.; Kunkel, S.L.; Polverini, P.J.; Glass, M.; Burdick, M.D.; Strieter, R.M. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J. Clin. Invest., 1996, 97(12), 2792-2802.
[http://dx.doi.org/10.1172/JCI118734] [PMID: 8675690]
[26]
Schadendorf, D.; Möller, A.; Algermissen, B.; Worm, M.; Sticherling, M.; Czarnetzki, B.M. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J. Immunol., 1993, 151(5), 2667-2675.
[PMID: 8360485]
[27]
Mueller, B.M.; Reisfeld, R.A.; Edgington, T.S.; Ruf, W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc. Natl. Acad. Sci. USA, 1992, 89(24), 11832-11836.
[http://dx.doi.org/10.1073/pnas.89.24.11832] [PMID: 1465406]
[28]
Ueno, T.; Toi, M.; Koike, M.; Nakamura, S.; Tominaga, T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br. J. Cancer, 2000, 83(2), 164-170.
[http://dx.doi.org/10.1054/bjoc.2000.1272] [PMID: 10901365]
[29]
Seto, S.; Onodera, H.; Kaido, T.; Yoshikawa, A.; Ishigami, S.; Arii, S.; Imamura, M. Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer, 2000, 88(2), 295-301.
[http://dx.doi.org/10.1002/(SICI)1097-0142(20000115)88:2<295::AID-CNCR8>3.0.CO;2-U] [PMID: 10640960]
[30]
Kakkar, A.K.; Chinswangwatanakul, V.; Lemoine, N.R.; Tebbutt, S.; Williamson, R.C. Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma. Br. J. Surg., 1999, 86(7), 890-894.
[http://dx.doi.org/10.1046/j.1365-2168.1999.01153.x] [PMID: 10417560]
[31]
Koomägi, R.; Volm, M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int. J. Cancer, 1998, 79(1), 19-22.
[http://dx.doi.org/10.1002/(SICI)1097-0215(19980220)79:1<19::AID-IJC4>3.0.CO;2-Z] [PMID: 9495352]
[32]
Bromberg, M.E.; Konigsberg, W.H.; Madison, J.F.; Pawashe, A.; Garen, A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc. Natl. Acad. Sci. USA, 1995, 92(18), 8205-8209.
[http://dx.doi.org/10.1073/pnas.92.18.8205] [PMID: 7667269]
[33]
Mueller, B.M.; Ruf, W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J. Clin. Invest., 1998, 101(7), 1372-1378.
[http://dx.doi.org/10.1172/JCI930] [PMID: 9525979]
[34]
Wilcox, J.N.; Smith, K.M.; Schwartz, S.M.; Gordon, D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc. Natl. Acad. Sci. USA, 1989, 86(8), 2839-2843.
[http://dx.doi.org/10.1073/pnas.86.8.2839] [PMID: 2704749]
[35]
Kaikita, K.; Ogawa, H.; Yasue, H.; Takeya, M.; Takahashi, K.; Saito, T.; Hayasaki, K.; Horiuchi, K.; Takizawa, A.; Kamikubo, Y.; Nakamura, S. Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. Arterioscler. Thromb. Vasc. Biol., 1997, 17(10), 2232-2237.
[http://dx.doi.org/10.1161/01.ATV.17.10.2232] [PMID: 9351394]
[36]
Erlich, J.H.; Holdsworth, S.R.; Tipping, P.G. Tissue factor initiates glomerular fibrin deposition and promotes major histocompatibility complex class II expression in crescentic glomerulonephritis. Am. J. Pathol., 1997, 150(3), 873-880.
[PMID: 9060825]
[37]
Erlich, J.H.; Boyle, E.M.; Labriola, J.; Kovacich, J.C.; Santucci, R.A.; Fearns, C.; Morgan, E.N.; Yun, W.; Luther, T.; Kojikawa, O.; Martin, T.R.; Pohlman, T.H.; Verrier, E.D.; Mackman, N. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am. J. Pathol., 2000, 157(6), 1849-1862.
[http://dx.doi.org/10.1016/S0002-9440(10)64824-9] [PMID: 11106558]
[38]
Himber, J.; Wohlgensinger, C.; Roux, S.; Damico, L.A.; Fallon, J.T.; Kirchhofer, D.; Nemerson, Y.; Riederer, M.A. Inhibition of tissue factor limits the growth of venous thrombus in the rabbit. J. Thromb. Haemost., 2003, 1(5), 889-895.
[http://dx.doi.org/10.1046/j.1538-7836.2003.00110.x] [PMID: 12871353]
[39]
Taylor, F.B., Jr; Chang, A.; Ruf, W.; Morrissey, J.H.; Hinshaw, L.; Catlett, R.; Blick, K.; Edgington, T.S.; Lethal, E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ. Shock, 1991, 33(3), 127-134.
[PMID: 2044206]
[40]
Kelley, R.F.; Refino, C.J.; O’Connell, M.P.; Modi, N.; Sehl, P.; Lowe, D.; Pater, C.; Bunting, S. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent. Blood, 1997, 89(9), 3219-3227.
[http://dx.doi.org/10.1182/blood.V89.9.3219] [PMID: 9129026]
[41]
Himber, J.; Refino, C.J.; Burcklen, L.; Roux, S.; Kirchhofer, D. Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig. Thromb. Haemost., 2001, 85(3), 475-481.
[http://dx.doi.org/10.1055/s-0037-1615608] [PMID: 11307818]
[42]
Himber, J.; Kirchhofer, D.; Riederer, M.; Tschopp, T.B.; Steiner, B.; Roux, S.P. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb. Haemost., 1997, 78(3), 1142-1149.
[http://dx.doi.org/10.1055/s-0038-1657701] [PMID: 9308768]
[43]
Harker, L.A.; Hanson, S.R.; Wilcox, J.N.; Kelly, A.B. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis, 1996, 26(Suppl. 1), 76-82.
[PMID: 8904178]
[44]
Suleymanov, O.D.; Szalony, J.A.; Salyers, A.K.; LaChance, R.M.; Parlow, J.J.; South, M.S.; Wood, R.S.; Nicholson, N.S. Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model. J. Pharmacol. Exp. Ther., 2003, 306(3), 1115-1121.
[http://dx.doi.org/10.1124/jpet.103.052779] [PMID: 12829728]
[45]
Szalony, J.A.; Suleymanov, O.D.; Salyers, A.K.; Panzer-Knodle, S.G.; Blom, J.D.; LaChance, R.M.; Case, B.L.; Parlow, J.J.; South, M.S.; Wood, R.S.; Nicholson, N.S. Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time. Thromb. Res., 2003, 112(3), 167-174.
[http://dx.doi.org/10.1016/j.thromres.2003.10.017] [PMID: 14967414]
[46]
Gardiner, E.J.; Willett, P.; Artymiuk, P.J. Graph-theoretic techniques for macromolecular docking. J. Chem. Inf. Comput. Sci., 2000, 40(2), 273-279.
[http://dx.doi.org/10.1021/ci990262o] [PMID: 10761128]
[47]
SeeSAR. Hoflack FlexX version 3.1.2; BioSolveIT GmbH, Sankt Augustin, Germany, 2020. Available from: www.biosolveit.de/SeeSAR/#FlexX.
[48]
Zhang, X.; Glunz, P.W.; Jiang, W.; Schmitt, A.; Newman, M.; Barbera, F.A.; Bozarth, J.M.; Rendina, A.R.; Wei, A.; Wen, X.; Rossi, K.A.; Luettgen, J.M.; Wong, P.C.; Knabb, R.M.; Wexler, R.R.; Scott Priestley, E. Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF-FVIIa inhibitors. Bioorg. Med. Chem. Lett., 2013, 23(6), 1604-1607.
[http://dx.doi.org/10.1016/j.bmcl.2013.01.094] [PMID: 23416003]
[49]
Ostrem, J.A.; al-Obeidi, F.; Safar, P.; Safarova, A.; Stringer, S.K.; Patek, M.; Cross, M.T.; Spoonamore, J.; LoCascio, J.C.; Kasireddy, P.; Thorpe, D.S.; Sepetov, N.; Lebl, M.; Wildgoose, P.; Strop, P. Discovery of a novel, potent, and specific family of factor Xa inhibitors via combinatorial chemistry. Biochemistry, 1998, 37(4), 1053-1059.
[http://dx.doi.org/10.1021/bi971147e] [PMID: 9454596]
[50]
Maas, J.W.; Le Noble, F.A.C.; Dunselman, G.A.J.; de Goeij, A.F.; Struyker Boudier, H.A.; Evers, J.L.H. The chick embryo chorioallantoic membrane as a model to investigate the angiogenic properties of human endometrium. Gynecol. Obstet. Invest., 1999, 48(2), 108-112.
[http://dx.doi.org/10.1159/000010150] [PMID: 10461001]
[51]
Yasri, A.; Berthelot, D.; Gijsen, H.; Thielemans, T.; Marichal, P.; Engels, M.; Hoflack, J. REALISIS: a medicinal chemistry-oriented reagent selection, library design, and profiling platform. J. Chem. Inf. Comput. Sci., 2004, 44(6), 2199-2206.
[http://dx.doi.org/10.1021/ci049879i] [PMID: 15554690]
[52]
Lu, Q.; Lv, M.; Xu, E.; Shao, F.; Feng, Y.; Yang, J.; Shi, L. Recombinant hirudin suppresses the viability, adhesion, migration and invasion of Hep-2 human laryngeal cancer cells. Oncol. Rep., 2015, 33(3), 1358-1364.
[http://dx.doi.org/10.3892/or.2015.3717] [PMID: 25592110]
[53]
Liang, G.; Bowen, J.P. Development of trypsin-like serine protease inhibitors as therapeutic agents: opportunities, challenges, and their unique structure-based rationales. Curr. Top. Med. Chem., 2016, 16(13), 1506-1529.
[54]
Parlow, J.J.; Case, B.L.; Dice, T.A.; Fenton, R.L.; Hayes, M.J.; Jones, D.E.; Neumann, W.L.; Wood, R.S.; Lachance, R.M.; Girard, T.J.; Nicholson, N.S.; Clare, M.; Roderick, I.; Stegeman, A.; Stevens, A.M.; Stallings, W.C.; Kurumbail, R.G.; South, M.S. Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex. J. Med. Chem., 2003, 46(19), 4050-4062.
[PMID: 12954058]
[55]
Zbinden, K.G.; Obst-Sander, U.; Hilpert, K.; Kühne, H.; Banner, D.W.; Böhm, H-J.; Stahl, M.; Ackermann, J.; Alig, L.; Weber, L.; Wessel, H.P.; Riederer, M.A.; Tschopp, T.B.; Lavé, T. Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors. Bioorg. Med. Chem. Lett., 2005, 15(23), 5344-5352.
[http://dx.doi.org/10.1016/j.bmcl.2005.04.079] [PMID: 16213138]
[56]
Parlow, J.J.; Kurumbail, R.G.; Stegeman, R.A.; Stevens, A.M.; Stallings, W.C.; South, M.S. Design, synthesis, and crystal structure of selective 2-pyridone tissue factor VIIa inhibitors. J. Med. Chem., 2003, 46(22), 4696-4701.
[http://dx.doi.org/10.1021/jm0301686] [PMID: 14561089]
[57]
Parlow, J.J.; Stevens, A.M.; Stegeman, R.A.; Stallings, W.C.; Kurumbail, R.G.; South, M.S. Synthesis and crystal structures of substituted benzenes and benzoquinones as tissue factor VIIa inhibitors. J. Med. Chem., 2003, 46(20), 4297-4312.
[http://dx.doi.org/10.1021/jm030233b] [PMID: 13678408]
[58]
Susarchyk, W.A.; Bolton, S.A.; Herpin, T.; Bisacchi, G.S.; Pi, Z.; Priestley, E.S. Ureido-substituted aniline compounds useful as serine protease inhibitors. U.S. Patent 6,846,838, 2005.
[59]
Chi, L.; Leadley, R.J., Jr; Peng, Y-W. Method for direct measurement of coagulation factor VIIa activity in plasma. U.S. Patent 6,773,896, 2004.
[60]
Bissachi, G.S.; Sutton, J.C.; Wu, S.C. Acid derivatives useful as serine protease inhibitors. U.S. Patent 6,713,467 2004.
[61]
Kingler, O.; Schudok, M.; Zoller, G.; Heinelt, U.; Defossa, E.; Matter, H.; Safar, P. Factor VIIa inhibitors. U.S. Patent 6,500,803, 2002.
[62]
Berryman, K.A.; Downing, D.M.; Dudley, D.A.; Edmunds, J.J.; Narasimhan, L.S.; Rapundalo, S.T. Benzoxazinones/benzothiazinones as serine protease inhibitors. U.S. Patent 6,509,335, 2003.
[63]
Kelley, R.F.; Lazarus, R.A.; Lee, G.F. Factor VIIA inhibitors. U.S. Patent 5,874,407, 1997.
[64]
Zhang, X. Amino-bicyclic pyrazinones and pyridinones as coagulation serine protease inhibitors. U.S. Patent 7,037,911, 2003.
[65]
Dudley, D.A.; Edmunds, J.J. Quinoxalinones as serine protease inhibitors. U.S. Patent 6,916,805, 2002.
[66]
Dudley, D.A.; Edmunds, J.J. Quinolones as serine protease inhibitors. U.S. Patent 6,855,726, 2000.

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy